NOW
AVAILABLE
93.3%
Just in
of Atrial Tachycardia successfully interrupted1*
faster when mapping with the PENTARAY® Catheter and pattern matching filter2**
20%
higher success rate when treated with the PENTARAY® Catheter4§
click
<20sec3
VT free survival rate (%)
12x
1
Logrank P=0.009
100%
PENTARAY® Catheter 80%
(n=73)
60%
No multipolar catheter
40%
(n=52)
20% 0% 0
500
1000
Follow-up (days) at 500 days follow-up after ventricular ablation compared with the focal ablation catheter, in a single center study4
Further Insight, Further Efficiency in mapping all your complex arrhythmias *In a single center study, after the first ablation set **Compared to the focal ablation catheter §Ischemic ventricular tachycardia in a single center study 1. Luther. V. et al. A Prospective Study of Ripple Mapping in Atrial Tachycardias. CIRCEP. 2016 2. Body Surface Morphology Matching Pre-Clinical Evidence Report. Test report: REP9819. June 2017 3. Imanli, H. et al, A Novel CARTO® Segmentation Software for Contrast enhanced Computed Tomography guided radiofrequency ablation in patients with atrial fibrillation. HRS poster. 2016 4. Jaïs, P. et al. Impact of New Technologies and Approaches for Post–Myocardial Infarction Ventricular Tachycardia Ablation During Long-Term Follow-Up. Circep. 2016 These products can only be used by healthcare professionals in EMEA. Important information: Prior to use, refer to the instructions for use supplied with this device for indications, contra-indications, side effects, warnings and precautions. The medical device herein mentioned is a class IIA and a regulated health product which bears the CE-Mark CE0344 (DEKRA). Manufacturer: Biosense Webster (Israel) Ltd. 4 Hatnufa Street Yokneam 2066717, ISRAEL EU Authorised Representative: Biosense Webster A Division of Johnson & Johnson Medical NV/SA Leonardo da Vincilaan 15, 1831 Diegem, BELGIUM © Johnson & Johnson Medical NV/SA 2018 | 078508-170813
V6_Onepager_A5-A4-and-245x342.indd 1 Untitled-1 1
06/06/201801:07 01:04 06/06/2018